15762 Results

People

  1. Hudis
    Hudis
  2. Offit
    Offit
  3. Zelefsky
    Zelefsky
  4. Giralt
    Giralt
  5. Robson
    Robson
  6. Yahalom
    Yahalom
  7. Wolden
    Wolden
  8. Coit
    Coit
  9. Marghoob
    Marghoob
  10. Tuttle
    Tuttle

Groups

  1. Survivorship Research (15762)
  2. Department of Medicine (9201)
  3. Population Sciences Research Program (5670)
  4. Solid Tumor Oncology Division (5183)
  5. Surgery (5130)
  6. Epidemiology and Biostatistics (3598)
  7. Division of Subspecialty Medicine (3242)
  8. Center for Hematologic Malignancies (2610)
  9. Biostatistics Service (2488)
  10. GSK Faculty (2413)
  1. "Survivorship Research"
Formats
  1. Journal Article (8899)
  2. Meeting Abstract (5192)
  3. Book Section (571)
  4. Review (357)
  5. Editorial (225)
  6. Research Letter (132)
  7. Conference Paper (104)
  8. Correspondence (91)
  9. Guidelines (85)
  10. Miscellaneous (76)
  11. Book Whole (30)
Groups
  1. Survivorship Research (15762)
  2. Department of Medicine (9201)
  3. Population Sciences Research Program (5670)
  4. Solid Tumor Oncology Division (5183)
  5. Surgery (5130)
  6. Epidemiology and Biostatistics (3598)

More Groups

People
  1. Clifford Hudis (905)
  2. Kenneth Offit (788)
  3. Michael Zelefsky (754)
  4. Sergio Giralt (684)
  5. Mark Robson (676)
  6. Joachim Yahalom (625)

More People

Years
  1. 2025 (231)
  2. 2024 (802)
  3. 2023 (892)
  4. 2022 (906)
  5. 2021 (922)
  6. 2020 (930)

More Years

Publications
  1. Journal of Clinical Oncology (1873)
  2. International Journal of Radiation Oncology, Biology, Physics (908)
  3. Blood (685)
  4. Annals of Surgical Oncology (599)
  5. Cancer Research (333)
  6. Cancer (331)

More Publications

Publishers
  1. Elsevier Inc. (2658)
  2. American Society of Clinical Oncology (2019)
  3. Springer (1542)
  4. Wiley Blackwell (806)
  5. Oxford University Press (787)
  6. American Society of Hematology (748)

More Publishers

Results (15762)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • State mandatory paid medical leave policies and survival among adults with cancer in the US
    Meeting Abstract

    Barnes, J. M.; Chino, F.; Johnson, K. J.; Zheng, Z.; Han, X.; Yabroff, R.; Johnston, K. J.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers
    Meeting Abstract

    Drago, J. Z.; Pareja, F.; Jhaveri, K. L.; Walsh, E. M.; Ku, G. Y.; Maron, S. B.; Janjigian, Y. Y.; Robson, M. E.; Reis-Filho, J. S.; Modi, S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Invasive disease free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab
    Meeting Abstract

    Chew, S.; Ferraro, E.; Chen, Y.; Barrio, A. V.; Kelly, D. W.; Modi, S.; Seidman, A. D.; Wen, H. Y.; Brogi, E.; Robson, M. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Prospective evaluation of pathologic response with neoadjuvant chemo-immunotherapy in metaplastic breast cancer
    Meeting Abstract

    Abuhadra, N.; Chen, Y.; Plitas, G.; Razavi, P.; Pareja, F.; Reis-Filho, J. S.; Wen, H. Y.; Khan, A. J.; Traina, T. A.; Downs-Canner, S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • State-of-the-art management of HER2-negative early breast cancer: Treatment patterns among healthcare professionals and concordance with expert recommendations
    Meeting Abstract

    Becker, M. N.; Abraham, J.; Kalinsky, K.; Spring, L.; Traina, T. A.; Quill, T. A.; Yardley, D. A.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Pathologic complete response after neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers
    Meeting Abstract

    Myers, S. P.; Sevilimedu, V.; Barrio, A. V.; Tadros, A.; Mamtani, A.; Robson, M. E.; Morrow, M.; Lee, M.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Real-world treatment patterns, healthcare resource utilization (HRU) and costs for relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Chimeric antigen receptor T-cell (CAR T) and monoclonal antibodies (MAB) therapies
    Meeting Abstract

    Feng, C.; Murphy, L.; Engel-Nitz, N.; Nguyen, A.; Patel, A.; DuCharme, M.; Fu, C.; Shah, G.
    Value in Health (2023)

    Fulltext@MSK | Save
  • A phase 1 study of savolitinib in recurrent, progressive, or refractory medulloblastoma, high-grade glioma, diffuse intrinsic pontine glioma, and central nervous system (CNS) tumors harboring met aberrations: A Pediatric Brain Tumor Consortium trial
    Meeting Abstract

    Salloum, R.; Huang, J.; Stewart, C. F.; Fuller, C.; Smolarek, T.; Lenzen, A.; Waanders, A. J.; Baxter, P.; Lindsay, H.; Robison, N.; more...
    Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • Non-invasive diagnosis of brainstem gliomas in pediatric, adolescent, and young adult patients through cerebrospinal fluid cell-free DNA sequencing
    Meeting Abstract

    Hill, K.; Giantini-Larsen, A.; Hickman, R. A.; Holle, B.; Alano, T.; Doe-Tetteh, S.; Bouvier, N.; Li, S.; Stockfisch, E.; Huereca, C.; more...
    Neuro-Oncology (2023)

    Fulltext@MSK | Save
  • Minimally-invasive diagnosis of diffuse leptomeningeal glioneuronal tumor (DLGNT) using cerebrospinal fluid cell-free DNA sequencing in pediatric and young adult patients
    Meeting Abstract

    Larsen, A. G.; Hill, K.; Hickman, R.; Bale, T.; Holle, B.; Mellinghoff, I.; Dunkel, I.; Souweidane, M.; Greenfield, J.; Sait, S. F.; more...
    Neuro-Oncology (2023)

    Fulltext@MSK | Save